Clinical Trial Update: Complement Inhibition in aHUS Dialysis Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a complement inhibitor in atypical hemolytic uremic syndrome patients on dialysis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 2 | Status: TERMINATED